Diagnosis: Type 1 Diabetes with Hypoglycemia from Excessive Insulin Dosing
This patient has type 1 diabetes (evidenced by the severely low C-peptide of 0.12 ng/ml, well below the 0.6 ng/ml threshold) and is experiencing hypoglycemia from insulin overdosing, requiring immediate reduction or discontinuation of insulin therapy while investigating the cause of her paradoxically elevated A1c.
Immediate Management
Reduce or temporarily discontinue all insulin therapy immediately to prevent recurrent hypoglycemia, which poses immediate risk of seizures, loss of consciousness, and death 1.
- The glucose of 69 mg/dl with C-peptide of 0.12 ng/ml (normal >0.6 ng/ml) indicates complete or near-complete β-cell failure 1
- The elevated A1c of 8.2% suggests chronic hyperglycemia, creating a paradox that requires explanation
- This discordance between current hypoglycemia and elevated A1c indicates either:
- Recent insulin dose escalation
- Improved insulin sensitivity from weight loss or other factors
- Laboratory artifact affecting A1c measurement 2
Diagnostic Evaluation Required
Obtain the following immediately:
- Complete medication review: Document all insulin types, doses, and timing. Look for recent dose increases or changes in insulin regimen
- Dietary history: Assess for decreased caloric intake, weight loss, or changes in eating patterns
- Screen for secondary causes of hypoglycemia:
- Cortisol level (rule out adrenal insufficiency)
- TSH (rule out hypothyroidism worsening)
- Comprehensive metabolic panel (assess renal function—declining kidney function reduces insulin clearance)
- Review for medications that enhance insulin sensitivity (hydroxychloroquine, pentamidine, quinolones) 3
Key Clinical Reasoning
The C-peptide of 0.12 ng/ml definitively rules out:
- Insulinoma (would have C-peptide ≥0.6 ng/ml with hypoglycemia) 1, 4
- Sulfonylurea ingestion (would elevate C-peptide)
- Insulin autoimmune syndrome (would have elevated C-peptide)
This patient has exogenous insulin-induced hypoglycemia in the setting of type 1 diabetes. The low C-peptide confirms absent endogenous insulin production 1.
Ongoing Management Algorithm
- Immediately reduce insulin doses by 30-50% or hold entirely until glucose stabilizes above 100 mg/dl
- Implement frequent glucose monitoring (every 2-4 hours initially, or continuous glucose monitoring)
- Educate on hypoglycemia recognition and treatment with 15g fast-acting carbohydrates
- Reassess A1c in 3 months after stabilizing glucose levels—the current A1c may reflect pre-adjustment hyperglycemia 5
- Restart insulin cautiously at lower doses once hypoglycemia resolves, titrating based on glucose patterns
Critical Pitfalls to Avoid
- Do not pursue workup for insulinoma or other endogenous hyperinsulinism—the suppressed C-peptide excludes these diagnoses 1
- Do not continue current insulin doses—this risks severe hypoglycemia with seizures or death
- Do not assume A1c accurately reflects recent glucose control—in complex cases with hematologic conditions or inflammation, A1c may be discordant with actual glycemia 2
- Do not overlook medication interactions—many drugs can potentiate insulin action or impair counterregulatory responses
Target Glucose Goals After Stabilization
Once hypoglycemia resolves, aim for:
- Fasting glucose: 80-130 mg/dl
- A1c: <7% (individualized based on hypoglycemia risk)
- Prioritize avoiding hypoglycemia over tight glycemic control given this patient's demonstrated vulnerability 6
The elevated A1c likely reflects glucose levels from weeks to months ago, before the current hypoglycemic state developed. The immediate priority is preventing life-threatening hypoglycemia by reducing insulin exposure 1.